{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:34:26Z","timestamp":1789043666665,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Accuray Incorporated"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.bbmt.2017.09.019","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T17:56:05Z","timestamp":1507830965000},"page":"301-307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Total Marrow Lymphoid Irradiation\/Fludarabine\/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation"],"prefix":"10.1016","volume":"24","author":[{"given":"Lindsay G.","family":"Jensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Stiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey Y.C.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joycelynne","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2017.09.019_bib0010","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/sj.bmt.1705739","article-title":"Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant","volume":"40","author":"Vicente","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0015","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1182\/blood-2007-02-076307","volume":"110","author":"Chang","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0020","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/bmt.2015.349","article-title":"Comparable outcomes between autologous and allogeneic transplant for adult acute myeloid leukemia in first CR","volume":"51","author":"Mizutani","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0025","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1182\/blood.V97.11.3669","volume":"97","author":"Blaise","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0030","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/blood.V83.9.2723.2723","article-title":"A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group","volume":"83","author":"Ringd\u00e9n","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0035","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/sj.bmt.1704198","article-title":"Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study","volume":"32","author":"Bunin","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0040","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1200\/JCO.2000.18.2.340","article-title":"Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia","volume":"18","author":"Davies","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0045","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1182\/blood.V76.9.1867.1867","article-title":"Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens","volume":"76","author":"Clift","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0050","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood.V92.4.1455","article-title":"Long-term follow-up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia","volume":"92","author":"Clift","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0055","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1002\/cncr.23405","article-title":"Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia: a report from the Childhood Cancer Survivor Study","volume":"112","author":"Mulrooney","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0060","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood-2011-01-331835","article-title":"Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS)","volume":"118","author":"Armenian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0065","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1182\/blood-2011-06-358226","article-title":"Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation","volume":"118","author":"Armenian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0070","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/sj.bmt.1705747","article-title":"Blood and marrow transplantation in elderly acute myeloid leukaemia patients: older certainly is not better","volume":"40","author":"Kiss","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0075","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.bbmt.2007.03.011","article-title":"Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the National Marrow Donor Program","volume":"13","author":"Giralt","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0080","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1182\/blood.V97.3.631","article-title":"Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation","volume":"97","author":"Giralt","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0085","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1083-8791(03)00241-6","article-title":"Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed","volume":"9","author":"Fung","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0090","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0095","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1118\/1.1576395","article-title":"Benchmarking beam alignment for a clinical helical tomotherapy device","volume":"30","author":"Balog","year":"2003","journal-title":"Med Phys"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0100","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.ijrobp.2006.10.047","article-title":"Image-guided total marrow and total lymphatic irradiation using helical tomotherapy","volume":"67","author":"Schultheiss","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0105","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijrobp.2012.03.033","article-title":"Dose escalation of total marrow irradiation with concurrent chemotherapy in patients with advanced acute leukemia undergoing allogeneic hematopoietic cell transplantation","volume":"85","author":"Wong","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0110","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.bbmt.2005.10.026","article-title":"Targeted total marrow irradiation using three-dimensional image-guided tomographic intensity-modulated radiation therapy: an alternative to standard total body irradiation","volume":"12","author":"Wong","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0115","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ijrobp.2008.04.071","article-title":"Image-guided total-marrow irradiation using helical tomotherapy in patients with multiple myeloma and acute leukemia undergoing hematopoietic cell transplantation","volume":"73","author":"Wong","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0120","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1182\/blood-2010-06-288357","article-title":"Phase 1\/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies","volume":"117","author":"Rosenthal","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0125","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1182\/blood.V120.21.222.222","article-title":"Matched cohort analysis of allogeneic hematopoietic cell transplantation (HCT) with total marrow irradiation\/fludarabine\/melphalan (TFM) versus fludarabine\/melphalan (FM) conditioning for acute leukemia","volume":"120","author":"Rosenthal","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0130","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0135","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0140","first-page":"1","article-title":"Statistical methods in cancer research. Volume II - The design and analysis of cohort studies","volume":"82","author":"Breslow","year":"1987","journal-title":"IARC Sci Publ"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0145","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0150","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0155","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1200\/JCO.2015.62.7273","volume":"33","author":"Devine","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0160","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.bbmt.2013.05.001","volume":"19","author":"Slack","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0165","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/bmt.2012.236","article-title":"Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT","volume":"48","author":"Martino","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0170","author":"Pasquini"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0175","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1097\/TP.0000000000001538","article-title":"The addition of low-dose total body irradiation to fludarabine and melphalan conditioning in haplocord transplantation for high-risk hematological malignancies","volume":"101","author":"Choe","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0180","doi-asserted-by":"crossref","first-page":"E97","DOI":"10.1002\/ajh.23974","article-title":"Addition of low dose total body irradiation to fludarabine melphalan reduced intensity conditioning is feasible, tolerable, and may improve outcomes in patients with high-risk acute myeloid leukaemia and other high risk myeloid malignancies","volume":"90","author":"Gifford","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0185","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/sj.bmt.1705278","article-title":"Total body irradiation, fludarabine, melphalan, and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematologic malignancies","volume":"37","author":"Petropoulos","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0190","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"Moreau","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0195","first-page":"71","article-title":"CT-based analysis of dose homogeneity in total body irradiation using lateral beam","volume":"5","author":"Hui","year":"2004","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0200","doi-asserted-by":"crossref","first-page":"S639","DOI":"10.1016\/j.ijrobp.2008.06.303","article-title":"Investigation of helical tomotherapy (HT) for total body irradiation and its comparison to conventional extended SSD technique","volume":"72","author":"Zhuang","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0205","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/cncr.29163","article-title":"Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"121","author":"Baron","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0210","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s12185-014-1684-x","article-title":"Comparison of reduced conditionings combining fludarabine with melphalan or 3-day busulfan in patients allografted for myeloid neoplasms","volume":"100","author":"Raida","year":"2014","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0215","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1046\/j.1365-2141.2001.03153.x","article-title":"Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study","volume":"115","author":"Martino","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0220","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/sj.bmt.1703652","article-title":"Fludarabine\/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma","volume":"30","author":"Giralt","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0225","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1083-8791(03)00128-9","article-title":"Graft-versus-host disease, donor chimerism, and organ toxicity in stem cell transplantation after conditioning with fludarabine and melphalan","volume":"9","author":"Ritchie","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0230","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2003-11-3750","article-title":"Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0235","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.bbmt.2016.07.006","article-title":"Fludarabine\/busulfan versus fludarabine\/melphalan conditioning in patients undergoing reduced-intensity conditioning hematopoietic stem cell transplantation for lymphoma","volume":"22","author":"Kekre","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0240","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1158\/1078-0432.CCR-10-1912","article-title":"Total marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma","volume":"17","author":"Somlo","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2017.09.019_bib0245","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.bbmt.2017.01.067","article-title":"Phase I trial of total marrow and lymphoid irradiation transplantation conditioning in patients with relapsed\/refractory acute leukemia","volume":"23","author":"Stein","year":"2017","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117307619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117307619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:00:41Z","timestamp":1761058841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879117307619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S1083879117307619"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.09.019","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Total Marrow Lymphoid Irradiation\/Fludarabine\/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}